Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations.
Myrto KostopoulouChetan B MukhtyarGeorge K BertsiasDimitrios T BoumpasAntonis FanouriakisPublished in: Annals of the rheumatic diseases (2024)
Anifrolumab and belimumab achieve better disease control than standard of care in extrarenal SLE, while combination therapies with belimumab and voclosporin attained higher response rates in high-quality RCTs in LN. Remission and low disease activity are associated with favourable long-term outcomes. In patients achieving these targets, GC and immunosuppressive therapy may gradually be tapered. Cite Now.
Keyphrases
- systemic lupus erythematosus
- disease activity
- rheumatoid arthritis patients
- ankylosing spondylitis
- end stage renal disease
- juvenile idiopathic arthritis
- ejection fraction
- newly diagnosed
- rheumatoid arthritis
- healthcare
- peritoneal dialysis
- chronic kidney disease
- prognostic factors
- stem cells
- pain management
- quality improvement
- bone marrow
- patient reported outcomes
- mesenchymal stem cells
- chronic pain
- affordable care act
- simultaneous determination